Membrane Fusion Inhibition, Immune Modulation, and Cholesterol Synthesis Dysregulation During Dengue Virus Inhibition by 25-Hydroxycholesterol
The paper investigated how 25-hydroxycholesterol (25-HC) inhibits dengue virus infection, focusing on host membrane fusion, cholesterol metabolism, lipid raft organization, and immune signaling. Using mechanistic studies and transcriptomic analyses, the authors found that 25-HC disrupts DENV envelope (E)-protein binding and viral membrane fusion by altering cholesterol distribution, suppresses cholesterol biosynthesis pathways required for viral replication while increasing lipid droplet formation and stress-response pathways, and primes innate immune responses including NLRP3 inflammasome and MAPK signaling with selective interferon-stimulated gene modulation. The authors also reported synergistic antiviral effects of 25-HC when combined with direct-acting antivirals such as Remdesivir. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via keyword match in the upstream search index.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Full text
1,957 characters
· extracted from
oa-doi-fallback
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-05-20T01:45:00.602351+00:00